Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

ASCO Chicago 2016

ASCO Chicago 2016 special issue ASCO 2016 can hope for long-term survival. Also, Preface phase I data on the DLL3-targeted anti- body–drug conjugate rovalpituzumab tesirine suggest that it has clinically rel- Dear Colleagues, evant activity in the SCLC population. One quarter of the abstracts submit- Lung cancer mortality rates for both ted for this year’s ASCO Congress were men and women have been declining focussed on the topic of immunother- in recent years. Early detection, re- apy. According to updates of pivotal tri- fined understanding of tumour biol- als, sustained benefits can be expected ogy, and a variety of novel treatment in a minority of patients with these options have made these advances drugs. Combination immunotherapy possible. Nevertheless, lung cancer is consisting of nivolumab and ipili- still the leading cause of cancer death mumab may provide benefits over in the United States and worldwide, nivolumab monotherapy in advanced survival improvements when all driver prompting the scientific community to NSCLC of any histology. However, mo- mutations were considered. Mini- persevere in their research efforts and lecularly targeted therapies remain the mally invasive techniques are gaining to extend them to areas that have tra- preferred therapeutic choice in the first ground, due to their http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png memo - Magazine of European Medical Oncology Springer Journals

Loading next page...
 
/lp/springer-journals/asco-chicago-2016-YMhXCB70Xp

References (0)

References for this paper are not available at this time. We will be adding them shortly, thank you for your patience.

Publisher
Springer Journals
Copyright
Copyright © 2016 by Springer-Verlag Wien
Subject
Medicine & Public Health; Oncology; Medicine/Public Health, general
ISSN
1865-5041
eISSN
1865-5076
DOI
10.1007/s12254-016-0277-1
Publisher site
See Article on Publisher Site

Abstract

special issue ASCO 2016 can hope for long-term survival. Also, Preface phase I data on the DLL3-targeted anti- body–drug conjugate rovalpituzumab tesirine suggest that it has clinically rel- Dear Colleagues, evant activity in the SCLC population. One quarter of the abstracts submit- Lung cancer mortality rates for both ted for this year’s ASCO Congress were men and women have been declining focussed on the topic of immunother- in recent years. Early detection, re- apy. According to updates of pivotal tri- fined understanding of tumour biol- als, sustained benefits can be expected ogy, and a variety of novel treatment in a minority of patients with these options have made these advances drugs. Combination immunotherapy possible. Nevertheless, lung cancer is consisting of nivolumab and ipili- still the leading cause of cancer death mumab may provide benefits over in the United States and worldwide, nivolumab monotherapy in advanced survival improvements when all driver prompting the scientific community to NSCLC of any histology. However, mo- mutations were considered. Mini- persevere in their research efforts and lecularly targeted therapies remain the mally invasive techniques are gaining to extend them to areas that have tra- preferred therapeutic choice in the first ground, due to their

Journal

memo - Magazine of European Medical OncologySpringer Journals

Published: Aug 4, 2016

There are no references for this article.